Reproductive Endocrinology Practice Questions

Q: A 30-year-old female presents with complaints of lethargy, anorexia, weight loss, and secondary amenorrhea. She has a history of postpartum hemorrhage and failed lactation. Which of the following is the most probable diagnosis?

Sheehan's syndrome. ### Explanation **Correct Answer: A. Sheehan's syndrome** **Why it is correct:** Sheehan’s syndrome is **postpartum hypopituitarism** caused by ischemic necrosis of the anterior pituitary gland. During pregnancy, the pituitary gland enlarges (hypertrophies), making it highly susceptible to ischemia if severe hypotension occurs due to **postpartum hemorrhage (PPH)**. The clinical presentation follows a pattern of progressive pituitary hormone deficiency: * **Prolactin deficiency:** Leads to **failure of lactation** (often the earliest sign). * **Gonadotropin (FSH/LH) deficiency:** Leads to **secondary amenorrhea** and loss of pubic/axillary hair. * **ACTH and TSH deficiency:** Causes lethargy, anorexia, weight loss, and hypotension. **Why the other options are incorrect:** * **B. Empty sella syndrome:** This involves a herniation of the subarachnoid space into the sella turcica, flattening the pituitary. While it can cause hypopituitarism, it is not classically associated with a specific history of PPH. * **C. Kallmann syndrome:** A genetic condition characterized by **hypogonadotropic hypogonadism and anosmia** (loss of smell). It presents as primary amenorrhea, not secondary amenorrhea following childbirth. * **D. Asherman syndrome:** This involves intrauterine adhesions (synechiae) usually following over-zealous D&C. While it causes secondary amenorrhea, it **does not affect systemic hormones**; therefore, lactation, thyroid, and adrenal functions remain normal. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest Sign:** Failure of lactation (due to prolactin deficiency). * **Most Common Initial Symptom:** Secondary amenorrhea. * **Investigation of Choice:** MRI of the pituitary (shows an empty sella in late stages). * **Management:** Lifelong hormone replacement therapy (Cortisol and Thyroid hormones must be replaced before Growth Hormone or Estrogen).

Q: Hyperprolactinemia results in which of the following?

Hypogonadotropic hypogonadism. ### Explanation **Mechanism of Action (Why B is correct):** Hyperprolactinemia causes infertility and menstrual irregularities primarily by interfering with the hypothalamic-pituitary-ovarian (HPO) axis. High levels of prolactin inhibit the **pulsatile release of GnRH** (Gonadotropin-Releasing Hormone) from the hypothalamus. * Reduced GnRH leads to decreased secretion of **FSH and LH** from the anterior pituitary. * Low gonadotropins (FSH/LH) result in low estrogen levels (hypogonadism). Because the primary defect is at the level of the hypothalamus/pituitary, it is classified as **Hypogonadotropic Hypogonadism**. **Analysis of Incorrect Options:** * **A. Chronic Anovulation:** While hyperprolactinemia *causes* chronic anovulation, "Hypogonadotropic hypogonadism" is the more fundamental pathophysiological description of the hormonal state requested in this context. * **C. Androgen Insensitivity Syndrome (AIS):** This is a genetic condition (46,XY) where there is a resistance to androgens. It is unrelated to prolactin levels. * **D. Hypergonadotropic Hypogonadism:** This occurs in primary ovarian failure (e.g., Turner Syndrome, Premature Ovarian Insufficiency), where FSH/LH are elevated because the pituitary is trying to stimulate non-functional ovaries. **NEET-PG High-Yield Pearls:** * **Clinical Presentation:** The classic triad is **Amenorrhea, Galactorrhea, and Infertility**. * **Drug-Induced:** The most common pharmacological cause is **Antipsychotics** (due to Dopamine antagonism). * **Hook Effect:** In cases of giant adenomas, extremely high prolactin can paradoxically show a low lab value; serial dilution is required for diagnosis. * **Treatment:** Medical management with **Dopamine agonists** (Cabergoline > Bromocriptine) is the first-line treatment, even for large macroprolactinomas. Surgery is reserved for refractory cases.

Q: The Fern test is indicative of which physiological change?

Presence of Sodium Chloride (NaCl) under estrogenic effect. **Explanation:** The **Fern test** (arborization) is a classic clinical test used to assess the estrogenic status of a patient. 1. **Why Option B is Correct:** Under the influence of **estrogen** (predominantly during the follicular phase), cervical mucus becomes thin, watery, and alkaline. High levels of estrogen lead to an increased concentration of **Sodium Chloride (NaCl)** in the mucus. When this mucus is spread on a glass slide and allowed to air-dry, the crystallization of NaCl creates a characteristic "palm-leaf" or "fern-like" pattern under the microscope. 2. **Why Other Options are Incorrect:** * **Option A:** **Progesterone** has the opposite effect. It makes the mucus thick, cellular, and acidic, which inhibits crystallization. This is known as the "smear pattern" or "non-ferning" effect, typical of the luteal phase or pregnancy. * **Option C:** While LH and FSH regulate the cycle, the Fern test specifically measures the end-organ response (cervical mucus) to steroid hormones, not the gonadotropins themselves. * **Option D:** While the glands do secrete the mucus, the "Fern" pattern specifically refers to the chemical crystallization of salts, not the mere presence of secretion. **High-Yield NEET-PG Pearls:** * **Peak Ferning:** Occurs between days 12–16 of a normal menstrual cycle (pre-ovulatory estrogen peak). * **Disappearance of Ferning:** If ferning disappears after day 21, it indicates successful **ovulation** (due to progesterone production by the corpus luteum). * **Clinical Use:** Used to detect ovulation, assess estrogen deficiency, or confirm the **Premature Rupture of Membranes (PROM)**, as amniotic fluid also shows a positive fern test. * **Spinnbarkeit Effect:** Another estrogenic marker where cervical mucus can be stretched into a long thread (usually >8-10 cm) just before ovulation.

Q: Which of the following is the best indicator of ovarian reserve?

FSH. **Explanation:** Ovarian reserve refers to the quantity and quality of the remaining oocytes in the ovaries. Among the options provided, **Day 3 FSH (Follicle Stimulating Hormone)** is the most established traditional biochemical marker used to predict ovarian response. **Why FSH is the correct answer:** As the pool of follicles decreases with age or premature ovarian failure, there is a decline in **Inhibin B** and **Estradiol** production. This loss of negative feedback on the pituitary gland leads to a compensatory rise in FSH levels. A high basal FSH (typically >10-12 mIU/mL) measured on Day 2 or 3 of the menstrual cycle is a specific, though late, indicator of diminished ovarian reserve. **Analysis of Incorrect Options:** * **B. Estradiol:** While measured on Day 3 alongside FSH, it is not a primary indicator. High early-cycle estradiol (>60-80 pg/mL) can falsely suppress FSH into the "normal" range, masking a diminished reserve. * **C. LH:** Luteinizing hormone is primarily used to track the mid-cycle surge for ovulation or to diagnose PCOS; it does not independently reflect the oocyte pool. * **D. FSH/LH ratio:** An elevated ratio (>2:1 or 3:1) may suggest declining reserve even if FSH is normal, but it is less clinically validated and less sensitive than FSH alone. **NEET-PG High-Yield Pearls:** * **Best/Most Sensitive Marker:** **AMH (Anti-Müllerian Hormone)** is now considered the best overall marker because it is cycle-independent and reflects the size of the primordial follicle pool. * **Best Ultrasound Marker:** **Antral Follicle Count (AFC)** via transvaginal sonography. * **Earliest Marker to Decline:** Inhibin B. * **Note on the Question:** In exams, if AMH is not an option, **Day 3 FSH** is the gold-standard answer. If both are present, choose AMH.

Q: A patient is at risk for estrogen-dependent carcinoma, making estrogen contraindicated. To prevent vasomotor symptoms in such a patient, which drug is given?

Clonidine. **Explanation:** The management of vasomotor symptoms (hot flashes, night sweats) in patients with contraindications to Hormone Replacement Therapy (HRT)—such as those with estrogen-dependent cancers (e.g., breast or endometrial carcinoma)—requires non-hormonal alternatives. **Why Clonidine is Correct:** Clonidine is a centrally acting **alpha-2 adrenergic agonist**. Vasomotor symptoms are thought to be triggered by a narrowing of the thermoregulatory set-point in the hypothalamus, mediated by increased noradrenergic activity. Clonidine reduces central sympathetic outflow, thereby stabilizing the thermoregulatory center and reducing the frequency and severity of hot flashes. It is a well-recognized non-hormonal second-line treatment for menopausal symptoms. **Analysis of Incorrect Options:** * **Tamoxifen (Option A):** While used in breast cancer treatment, it is a Selective Estrogen Receptor Modulator (SERM) that acts as an anti-estrogen in the breast but can actually **exacerbate** vasomotor symptoms as a side effect. * **Conjugated Estrogen (Option B):** This is the gold standard for vasomotor symptoms but is strictly **contraindicated** in patients with estrogen-dependent carcinomas, as it can promote tumor growth. * **Yohimbine (Option D):** This is an alpha-2 antagonist (the opposite of clonidine) and is typically used for erectile dysfunction; it has no role in treating hot flashes. **High-Yield Clinical Pearls for NEET-PG:** * **First-line non-hormonal agents:** SSRIs (e.g., Paroxetine) and SNRIs (e.g., Venlafaxine) are currently preferred over Clonidine due to a better side-effect profile. * **Gabapentin:** Another effective non-hormonal option that acts on the calcium channels to reduce hot flashes. * **Tibolone:** A synthetic steroid with estrogenic, progestogenic, and androgenic properties; however, it is also generally avoided in active breast cancer cases.

Q: Which of the following factors has been implicated in the pathogenesis of ovarian hyperstimulation syndrome?

VEGF. **Explanation:** **Ovarian Hyperstimulation Syndrome (OHSS)** is a serious iatrogenic complication of controlled ovarian stimulation, characterized by increased capillary permeability leading to a fluid shift from the intravascular space to the "third space" (ascites, pleural effusion). **Why VEGF is the correct answer:** While hCG acts as the primary trigger for OHSS, **Vascular Endothelial Growth Factor (VEGF)** is the key **mediator** of its pathogenesis. Under the influence of hCG, the hyperstimulated granulosa cells overexpress VEGF and its receptor (VEGFR-2). VEGF acts on the vascular endothelium to increase **vascular permeability** by disrupting tight junctions. This leads to the massive fluid extravasation that defines the clinical features of OHSS. **Analysis of Incorrect Options:** * **hCG (Option B):** While hCG (exogenous or endogenous from pregnancy) is the *initiating factor* that triggers the cascade, it is not the direct mediator of capillary leak. VEGF is the specific factor "implicated in the pathogenesis" of the vascular changes. * **EGF & FGF (Options C & D):** Epidermal Growth Factor and Fibroblast Growth Factor are involved in follicular growth and angiogenesis but do not play a primary role in the acute increase in capillary permeability seen in OHSS. **High-Yield Clinical Pearls for NEET-PG:** * **Key Mediator:** VEGF (specifically VEGFR-2). * **Primary Trigger:** hCG (Human Chorionic Gonadotropin). * **Prevention:** Use of GnRH agonists for "triggering" instead of hCG, or "coasting" (withholding gonadotropins). * **Management:** Fluid resuscitation (Albumin is often used to maintain oncotic pressure) and Cabergoline (a dopamine agonist that inhibits VEGF receptor phosphorylation). * **Risk Factor:** PCOS patients are at the highest risk for developing OHSS.

Q: What is the most common cause of abortion in the first trimester?

Embryonic defect. **Explanation:** **Correct Answer: C. Embryonic defect** The most common cause of spontaneous abortion in the first trimester is an **embryonic defect**, specifically **chromosomal abnormalities**. Approximately 50–60% of all first-trimester miscarriages are attributed to genetic errors. Among these, **Autosomal Trisomy** is the most frequent (Trisomy 16 being the most common specific trisomy), followed by Monosomy X (Turner Syndrome) and Polyploidy. These defects usually result from errors in gametogenesis or fertilization rather than maternal factors, leading to non-viable embryos that the body naturally expels. **Why other options are incorrect:** * **A. Placental defect:** While placental issues (like circumvallate placenta or retroplacental hemorrhage) can cause pregnancy loss, they are more frequently associated with second-trimester losses or late pregnancy complications rather than early first-trimester abortions. * **B. Uterine defect:** Anatomical issues (e.g., septate uterus, submucosal fibroids, or cervical incompetence) are significant causes of **recurrent** pregnancy loss or mid-trimester abortions, but they are statistically less common than chromosomal defects in the first trimester. * **D. Ovarian defect:** Luteal phase deficiency (inadequate progesterone production by the corpus luteum) can lead to miscarriage, but it accounts for a very small percentage of cases compared to embryonic factors. **High-Yield NEET-PG Pearls:** * **Most common chromosomal abnormality:** Autosomal Trisomy (50%). * **Most common specific Trisomy:** Trisomy 16 (never seen in live births). * **Most common single chromosomal anomaly:** Monosomy X (45, X). * **Timing:** 80% of spontaneous abortions occur within the first 12 weeks of pregnancy.

Q: A patient diagnosed with hypogonadism has normal FSH and estradiol levels. According to the WHO classification of disorders of ovulation, to which type does this patient belong?

Type II. ### Explanation The WHO classification of ovulatory disorders is a high-yield topic for NEET-PG, categorizing patients based on the hormonal axis (Hypothalamus-Pituitary-Ovary). **1. Why Type II is Correct:** **WHO Type II (Eu-gonadotropic Eu-estrogenic)** is characterized by **normal FSH and normal Estradiol** levels. This is the most common category of ovulatory dysfunction (approx. 85%). The classic clinical example is **Polycystic Ovary Syndrome (PCOS)**. Although the hormones are within the "normal" range, the cyclical rhythm is disrupted, leading to oligo-ovulation or anovulation. **2. Why Other Options are Incorrect:** * **Type I (Hypogonadotropic Hypogonadism):** Characterized by **Low FSH and Low Estradiol**. This results from hypothalamic or pituitary failure (e.g., Kallmann syndrome, excessive exercise, or stress). * **Type III (Hypergonadotropic Hypogonadism):** Characterized by **High FSH and Low Estradiol**. This indicates **Premature Ovarian Failure (POF)** or Primary Ovarian Insufficiency; the pituitary is overworking to stimulate non-responsive ovaries. * **Type IV (Hyperprolactinemic Anovulation):** Though sometimes categorized separately, it involves elevated prolactin levels which inhibit GnRH pulsatility, leading to anovulation despite normal ovarian reserve. **3. Clinical Pearls for NEET-PG:** * **Most Common Type:** WHO Type II (PCOS). * **Treatment of Choice (Type I):** Pulsatile GnRH or Gonadotropins (hMG/FSH). * **Treatment of Choice (Type II):** Lifestyle modification followed by Letrozole (first-line) or Clomiphene Citrate. * **Progestogen Challenge:** Patients with Type II will have a **positive** withdrawal bleed (due to presence of estrogen), whereas Type I and Type III will usually be negative.

Question 1

A 30-year-old female presents with complaints of lethargy, anorexia, weight loss, and secondary amenorrhea. She has a history of postpartum hemorrhage and failed lactation. Which of the following is the most probable diagnosis?

Accepted Answer

Sheehan's syndrome

Answer

Empty sella syndrome

Answer

Kallmann syndrome

Answer

Asherman syndrome

Question 2

Hyperprolactinemia results in which of the following?

Accepted Answer

Hypogonadotropic hypogonadism

Answer

Chronic anovulation

Answer

Androgen insensitivity syndrome

Answer

Hypergonadotropic hypogonadism

Question 3

The Fern test is indicative of which physiological change?

Accepted Answer

Presence of Sodium Chloride (NaCl) under estrogenic effect

Answer

Presence of Sodium Chloride (NaCl) under progesterone effect

Answer

Luteinizing Hormone (LH)/Follicle-Stimulating Hormone (FSH) levels

Answer

Mucus secretion by glands

Question 4

Which of the following is the best indicator of ovarian reserve?

Accepted Answer

FSH

Answer

Estradiol

Answer

LH

Answer

FSH/LH ratio

Question 5

A 17-year-old girl presents with primary amenorrhea. On examination, there is absent breast development, but the vagina is normal. Ultrasound reveals a hypoplastic uterus, and bilateral ovaries are not visualized. What is the most likely diagnosis?

Accepted Answer

Turner syndrome

Answer

Swyer syndrome

Answer

Müllerian agenesis

Answer

Androgen insensitivity syndrome

Question 6

A patient is at risk for estrogen-dependent carcinoma, making estrogen contraindicated. To prevent vasomotor symptoms in such a patient, which drug is given?

Accepted Answer

Clonidine

Answer

Tamoxifen

Answer

Conjugated estrogen

Answer

Yombinine

Question 7

Which of the following factors has been implicated in the pathogenesis of ovarian hyperstimulation syndrome?

Accepted Answer

VEGF

Answer

hCG

Answer

EGF

Answer

FGF

Question 8

What is the most common cause of abortion in the first trimester?

Accepted Answer

Embryonic defect

Answer

Placental defect

Answer

Uterine defect

Answer

Ovarian defect

Question 9

A female patient presents with primary amenorrhea. She has a negative progesterone challenge test but a positive response to combined estrogen and progesterone administration. What is the most likely diagnosis?

Accepted Answer

Prolactinoma

Answer

Mullerian agenesis

Answer

Polycystic ovary disease (PCOD)

Answer

Asherman syndrome

Question 10

A patient diagnosed with hypogonadism has normal FSH and estradiol levels. According to the WHO classification of disorders of ovulation, to which type does this patient belong?

Accepted Answer

Type II

Answer

Type I

Answer

Type III

Answer

Type IV

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?